TY - JOUR
T1 - Barriers to Hematopoietic Cell Transplantation for Adults in the United States
T2 - A Systematic Review with a Focus on Age
AU - Flannelly, Colin
AU - Tan, Bryan E.Xin
AU - Tan, Jian Liang
AU - McHugh, Colin M.
AU - Sanapala, Chandrika
AU - Lagu, Tara
AU - Liesveld, Jane L.
AU - Aljitawi, Omar
AU - Becker, Michael W.
AU - Mendler, Jason H.
AU - Klepin, Heidi D.
AU - Stock, Wendy
AU - Wildes, Tanya M.
AU - Artz, Andrew
AU - Majhail, Navneet S.
AU - Loh, Kah Poh
N1 - Funding Information:
The authors thank Daniel Castillo for performing the systematic search and Dr. Susan Rosenthal for her editorial assistance. The study was presented as a poster at the 2018 American Society of Hematology Annual Meeting (December 1-4, 2018 in San Diego, CA). Financial disclosure: K.P.L. is supported by the National Cancer Institute at the National Institutes of Health (K99CA237744) and Wilmot Research Fellowship Award. T.L. is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health (R01 HL139985-01A1 and R01HL146884-01). H.D.K. is supported by National Institute on Aging at the National Institutes of Health (R33AG059206). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Conflict of interest statement: K.P.L. has served as a consultant to Pfizer and Seattle Genetics. T.L. has served as a consultant for the Yale Center for Outcomes Research and Evaluation, under contract to the Centers for Medicare & Medicaid Services, for which she has provided clinical and methodologic expertise and input on the development, reevaluation, and implementation of hospital outcome and efficiency measures. The views expressed in this manuscript do necessarily reflect those of the Yale Center for Outcomes Research and Evaluation or the Centers for Medicare and Medicaid Services. H.D.K. is a contributor to UpToDate. T.M.W. has served as a consultant for Seattle Genetics and Carevive Systems and received research funding from Janssen. W.S. has served as a consultant to Agios, Amgen, Kite, Jazz, Servier, Pfizer, Morphosys, and Adpative Biotechnologies and has received speaking honoraria from Pfizer and Abbvie. N.S.M. has served as a consultant to Anthem, served on the advisory board for Nkarta, and received honoraria from Mallinckrodt. All other authors declare no conflict of interest. Authorship statement: N.S.M. and K.P.L. conceived and designed the study. C.F. B.E.-X.T. J.L.T. and K.P.L. performed the analyses. C.F. and K.P.L. wrote the draft manuscript. All authors acquired, analyzed, or interpreted data and critically revised the manuscript. Financial disclosure: See Acknowledgments on page 2343.
Funding Information:
Conflict of interest statement: K.P.L. has served as a consultant to Pfizer and Seattle Genetics. T.L. has served as a consultant for the Yale Center for Outcomes Research and Evaluation, under contract to the Centers for Medicare & Medicaid Services, for which she has provided clinical and methodologic expertise and input on the development, reevaluation, and implementation of hospital outcome and efficiency measures. The views expressed in this manuscript do necessarily reflect those of the Yale Center for Outcomes Research and Evaluation or the Centers for Medicare and Medicaid Services. H.D.K. is a contributor to UpToDate. T.M.W. has served as a consultant for Seattle Genetics and Carevive Systems and received research funding from Janssen. W.S. has served as a consultant to Agios, Amgen, Kite, Jazz, Servier, Pfizer, Morphosys, and Adpative Biotechnologies and has received speaking honoraria from Pfizer and Abbvie. N.S.M. has served as a consultant to Anthem, served on the advisory board for Nkarta, and received honoraria from Mallinckrodt. All other authors declare no conflict of interest.
Funding Information:
Financial disclosure: K.P.L. is supported by the National Cancer Institute at the National Institutes of Health (K99CA237744) and Wilmot Research Fellowship Award. T.L. is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health (R01 HL139985-01A1 and R01HL146884-01). H.D.K. is supported by National Institute on Aging at the National Institutes of Health (R33AG059206). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2020 American Society for Transplantation and Cellular Therapy
PY - 2020/12
Y1 - 2020/12
N2 - Hematopoietic cell transplantation (HCT) is an effective treatment for many hematologic malignancies, and its utilization continues to rise. However, due to the difficult logistics and high cost of HCT, there are significant barriers to accessing the procedure; these barriers are likely greater for older patients. Although numerous factors may influence HCT access, no formal analysis has detailed the cumulative barriers that have been studied thus far. We conducted a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines to better categorize the barriers to access and referral to HCT, with a focus on the subgroup of older patients. We searched for articles published in English from PubMed, Embase, Cumulative Index for Nursing and Allied Health, and Cochrane Central Register of Controlled Trials between the database inception and January 31, 2020. We selected articles that met the following inclusion criteria: (1) study design: qualitative, cross-sectional, observational cohort, or mixed-method study designs; (2) outcomes: barriers related to patient and physician access to HCT; and (3) population: adults aged ≥18 years with hematologic malignancies within the United States. Abstracts without full text were excluded. QUALSYST methodology was used to determine article quality. Data on the barriers to access and referral for HCT were extracted, along with other study characteristics. We summarized the findings using descriptive statistics. We included 26 of 3859 studies screened for inclusion criteria. Twenty studies were retrospective cohorts and 4 were cross-sectional. There was 1 prospective cohort study and 1 mixed-method study. Only 1 study was rated as high quality, and 16 were rated as fair. Seventeen studies analyzed age as a potential barrier to HCT referral and access, with 16 finding older age to be a barrier. Other consistent barriers to HCT referral and access included nonwhite race (n = 16/20 studies), insurance status (n = 13/14 studies), comorbidities (n = 10/11 studies), and lower socioeconomic status (n = 7/8 studies). High-quality studies are lacking related to HCT barriers. Older age and nonwhite race were consistently linked to reduced access to HCT. To produce a more just health care system, strategies to overcome these barriers for vulnerable populations should be prioritized. Examples include patient and physician education, as well as geriatric assessment guided care models that can be readily incorporated into clinical practice.
AB - Hematopoietic cell transplantation (HCT) is an effective treatment for many hematologic malignancies, and its utilization continues to rise. However, due to the difficult logistics and high cost of HCT, there are significant barriers to accessing the procedure; these barriers are likely greater for older patients. Although numerous factors may influence HCT access, no formal analysis has detailed the cumulative barriers that have been studied thus far. We conducted a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines to better categorize the barriers to access and referral to HCT, with a focus on the subgroup of older patients. We searched for articles published in English from PubMed, Embase, Cumulative Index for Nursing and Allied Health, and Cochrane Central Register of Controlled Trials between the database inception and January 31, 2020. We selected articles that met the following inclusion criteria: (1) study design: qualitative, cross-sectional, observational cohort, or mixed-method study designs; (2) outcomes: barriers related to patient and physician access to HCT; and (3) population: adults aged ≥18 years with hematologic malignancies within the United States. Abstracts without full text were excluded. QUALSYST methodology was used to determine article quality. Data on the barriers to access and referral for HCT were extracted, along with other study characteristics. We summarized the findings using descriptive statistics. We included 26 of 3859 studies screened for inclusion criteria. Twenty studies were retrospective cohorts and 4 were cross-sectional. There was 1 prospective cohort study and 1 mixed-method study. Only 1 study was rated as high quality, and 16 were rated as fair. Seventeen studies analyzed age as a potential barrier to HCT referral and access, with 16 finding older age to be a barrier. Other consistent barriers to HCT referral and access included nonwhite race (n = 16/20 studies), insurance status (n = 13/14 studies), comorbidities (n = 10/11 studies), and lower socioeconomic status (n = 7/8 studies). High-quality studies are lacking related to HCT barriers. Older age and nonwhite race were consistently linked to reduced access to HCT. To produce a more just health care system, strategies to overcome these barriers for vulnerable populations should be prioritized. Examples include patient and physician education, as well as geriatric assessment guided care models that can be readily incorporated into clinical practice.
KW - Age
KW - Barriers
KW - Hematopoietic cell transplantation
KW - Race
UR - http://www.scopus.com/inward/record.url?scp=85092012345&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092012345&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2020.09.013
DO - 10.1016/j.bbmt.2020.09.013
M3 - Article
C2 - 32961375
AN - SCOPUS:85092012345
SN - 1083-8791
VL - 26
SP - 2335
EP - 2345
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 12
ER -